Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.48 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.48 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.48 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.48 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606162 | 0.84 | CASP3 (0.52) | CASP3CASP1PDE4APDE4BPDE4C | |
| SCHEMBL712931 | 0.83 | CA2 (0.65) | CASP3CA2CA1ACEGAA | |
| SCHEMBL697052 | 0.83 | CA2 (0.65) | CASP3CA2CA1ACEGAA | |
| SCHEMBL697053 | 0.83 | CA2 (0.65) | CASP3CA2CA1ACEGAA | |
| SCHEMBL7148922 | 0.83 | ACE (0.64) | CA2CA1ACE | |
| SCHEMBL6496041 | 0.83 | ACE (0.64) | CA2CA1ACE | |
| SCHEMBL29159682 | 0.81 | CA2 (0.63) | CASP3CA2CA1ACEGAA | |
| SCHEMBL6606570 | 0.81 | CTSG (0.43) | PDE4APDE4BPDE4CPDE4DPADI6 | |
| SCHEMBL20875154 | 0.79 | CTSL (0.50) | CASP3CASP1CA2CA1LMNA | |
| SCHEMBL20740123 | 0.79 | CTSL (0.50) | CASP3CASP1CA2CA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163208-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6632962-B2 | N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| US-20020132833-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-09-19 | — | — | US | disclosed |
| EP-1163208-A4 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1163208-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001010383-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132833-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP7 | CASP3 2/4885CASP1 1/4885PDE4A 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.